"Zaiding Pharmaceuticals and Anjin reached a global clinical research cooperation agreement."

On April 2nd, Reding Pharmaceuticals Limited announced a global clinical research collaboration with Amgen to evaluate the antibody-drug conjugate zocilurtatug pelitecan targeting delta-like ligand 3 in clinical stage by Reding Pharmaceuticals, in combination with Amgen's IMDELLTRA, a bispecific T cell engager therapy targeting DLL3, for the treatment of extensive-stage small cell lung cancer patients. As part of this collaboration agreement, Amgen will sponsor a global phase 1b study to evaluate the safety and efficacy of zoci in combination with IMDELLTRA in ES-SCLC patients. Reding Pharmaceuticals will retain full ownership of zoci and provide clinical trial drugs to Amgen.